Similar BCL-X but different BCL-2 levels in the two age groups of north African nasopharyngeal carcinomas

Cancer Detection and Prevention

Volumn 27, Issue 4, 2003, Pages 250-255

  Khabir, Abdelmajid ^a   Ghorbel, Abdelmoneem ^a   Daoud, Jamel ^a   Frikha, Mounir ^a   Drira, Mohamed Mokhtar ^a   Laplanche, Agnès ^b   Busson, Pierre ^c   Jlidi, Rachid ^a  

^a HABIB BOURGUIBA HOSPITAL   (Tunisia)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UMR 8126   (France)

Author keywords

EBNA1; Epstein Barr virus; Head and neck carcinomas; Pediatric malignancies

Indexed keywords

EID: 0041570140     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(03)00098-9     Document Type: Article

References (31)

1. IARC Working Group on the evaluation of carcinogenic risks to humans. Epstein-Barr virus and Kaposi's sarcoma Herpesvirus/Human Herpesvirus 8, vol. no. 70. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon, France: IARC; 1997.
2. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, editors. Cancer incidence in five continents, vol. VII. IARC Scientific Publications No. 143. Lyon: IARC; 1997.
3. Nicholls JM, Agathangellou A, Fung K, Zeng X, Niedobitek G. The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol 1997;183:164-8.
4. Nanbo A, Inoue K, Adachi-Takasawa K, Takada K. Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma. EMBO J 2002;21:954-65.
5. L and RAG genes are induced and the response to IL-2 enhanced in EμEBNA-1 transgenic mouse lymphocytes. Oncogene 2002;21:5182-7.
6. Decaussin G, Sbih-Lammali F, de Turenne-Tessier M, Bouguermouh A, Ooka T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res 2000;60:5584-8.
7. Gulley ML, Nicholls JM, Schneider BG, Amin MB, Ro JY, Geradts J. Nasopharyngeal carcinomas frequently lack the p16/MTS1 tumor suppressor protein but consistently express the retinoblastoma gene product. Am J Pathol 1998;152:865-9.
8. Lo KW, Kwong J, Hui AB, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001;61:3877-81.
9. Effert P, McCoy R, Abdel-Hamid M, et al. Alterations of the p53 gene in nasopharyngeal carcinoma. J Virol 1992;66:3768-75.
10. Lung ML, Hu Y, Cheng Y, Li MF, Tang CM, Sai-Ki O, Iggo RD. p53 inactivating mutations in Chinese nasopharyngeal carcinomas. Cancer Lett 1998;133:89-94.
11. Sheu LF, Chen A, Meng CL, Ho KC, Lin FG, Lee WH. Analysis of bcl-2 expression in normal, inflamed, dysplastic nasopharyngeal epithelia and nasopharyngeal carcinoma: association with p53 expression. Hum Pathol 1997;28:556-62.
12. Khabir A, Sellami A, Sakka M, et al. Contrasted frequencies of p53 accumulation in the two age groups of north African nasopharyngeal carcinomas. Clin Cancer Res 2000;6:3932-6.
13. Crook T, Nicholls JM, Brooks L, O'Nions J, Allday MJ. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000;19:3439-44.
14. Ali H, Al-Sarraf M. Chemotherapy in advanced nasopharyngeal cancer. Oncology 2000;14:1223-30.
15. Cammoun M, Vogt Hoerner G, Mourali N. Tumors of the nasopharynx in Tunisia: an anatomic and clinical study based on 143 cases. Cancer 1974;33:184-91.
16. Stiller CA. International variations in the incidence of childhood carcinomas. Cancer Epidemiol Biomarkers Prey 1994;3:305-10.
17. Sbih-Lammali F, Djennaoui D, Belaoui H, Bouguermouh A, Decaussin G, Ooka T. Transcriptional expression of Epstein-Barr virus genes and proto-oncogenes in north African nasopharyngeal carcinoma. J Med Virol 1996;49:7-14.
18. Lombardi F, Gasparini M, Gianni C, De Marie M, Molinari R, Pilotti S. Combined radiotherapy and chemotherapy in stages T3 and T4 nasopharyngeal carcinoma in children. Med Pediatr Oncol 1982;10:243-50.
19. Mertens R, Granzen B, Lassay L, Gademan G, Hess CF, Heiman G. Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91: Gesellschaft fur Padiatrische Onkologie und Hamatologie. Cancer 1997;80:951-9.
20. Berberoglu S, Ilhan I, Cetindag F, Sunter O. Nasopharyngeal carcinoma in Turkish children: review of 33 cases. Pediatr Hematol Oncol 2001;18:309-15.
21. Parkin DM, Iscovich J. Risk of cancer in migrants and their descendants in Israel. II. Carcinomas and germ-cell tumors. Int J Cancer 1997;70:654-60.
22. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 2000;97:6055-60.
23. D'Souza B, Rowe M, Walls D. The bfl-1 gene is transcriptionally upregulated by the Epstein-Barr virus LMPI, and its expression promotes the survival of a Burkitt's lymphoma cell line. J Virol 2000;74:6652-8.
24. Lu QL, Elia G, Lucas S, Thomas JA. Bcl-2 proto-oncogene expression in Epstein-Barr-virus associated nasopharyngeal carcinoma. Int J Cancer 1993;53:29-35.
25. Krajewska M, Krajewski S, Epstein, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-76.
26. Sjostrom J, Blomqvist C, von Boguslawski K, et al. The predictive value of Bcl-2, Bax, Bcl-xL, Bag-l, Fas, and Fas-L for chemotherapy response in advanced breast cancer. Clin Cancer Res 2002;8:811-6.
27. Erber WN, Willis JI, Hoffman GJ. An enhanced immunocytochemical method for staining bone marrow trephine sections. J Clin Pathol 1997;50:389-93.
28. Pena JC, Thompson CB, Recant W, Vokes EE, Rudin CM. Bcl-X and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer 1999;85:164-70.
29. Henderson S, Rowe M, Gregory C, et al. Induction of Bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B-cells from programmed cell death. Cell 1991;65:1107-15.
30. Sheng W, Decaussin G, Sumner S, Ooka T. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene 2001;20:1176-85.
31. Maalej M, Daoud J, Bouaouina N, et al. Clinical and evolutive aspects of nasopharyngeal T4 N0 neoplasms. Bull Cancer 1995;82:728-31.